A contract research organization that runs clinical trials and outsourced drug-development services for pharmaceutical, biotechnology, and medical device companies around the world. Founded in Dublin in 1990 by two doctors who started with a team of five, the name ICON is not an acronym — it was simply chosen to reflect the company's focus on clinical research. It even built a "Country-in-a-Box" service to help clients launch trials in unfamiliar markets.
20-F · Fiscal year ended Dec 31, 2025 · SEC filing ↗
ICON took a $465M Data Solutions impairment and operating income fell 57.1% to $443M in FY2025.
A $465M in the Data Solutions unit cut ICON's by more than half. rose 0.8% to $8.25B and held at 29.4%, but operating income fell 57.1% to $443M as a $364.2M charge and higher weighed on the year. The company enters 2026 with weaker reported earnings and a flagged internal-control weakness to resolve.
Key takeaways
A $364.2M and a $101.0M non-financial asset in the Data Solutions reporting unit drove down 57.1% to $442.8M, with both items non-cash and one-off.
rose 0.8% to $8,251.3M, led by Ireland and Rest of World while U.S. revenue declined 15.4%, a deeper drop than the 9.1% U.S. fall seen in 2024.
rose 4.4% to $6,075.7M, pushing the direct cost ratio to 73.6% from 71.0% on higher investigator and reimbursable costs, the main cause of margin pressure outside the impairments.
Section summaries
Quantitative and Qualitative Disclosures About Market Risk
Principal market risks are foreign currency and interest rate; the company uses forward contracts and active treasury management, with no open FX hedges at year-end.
⌄
Foreign currency risk arises from translation of non-U.S. operations into USD and from transaction exposures where contract currencies differ from cost currencies.
Outside the U.S., contracts are often priced in USD or euro while costs are incurred in multiple currencies, though some occurs.
fell 35.1% to $227.2M as PRA merger intangibles finished amortizing in July 2024, a recurring that did not offset the hit.
decreased to $1,036.2M from $1,286.7M in 2024, and the company repurchased $750M in shares while ending with $647.3M cash, up from $538.8M.
fell to $14.9B from $15.9B; top five customer concentration eased to 24.8% of from 25.0%.
What changed
The $15.9B flagged to watch in 2024 fell to $14.9B, a reduction rather than growth in .
U.S. , flagged after its 9.1% 2024 decline, fell further to -15.4% in 2025, signaling continued organic weakness in that market.
Restructuring execution flagged in 2024 yielded no stated sustained SG&A improvement; SG&A was not separately reported as improved this year.
repayment continued but was $3,396.4M, little changed from the prior year's balance, with 27% now variable-rate and unhedged per the risk section.
Days' outstanding was not reported for 2025, leaving the multi-year track from 31 to 54 to 47 days open.
What to watch
Track resolution of the material weaknesses in internal control and any filing-delisting or effect in 2026.
Watch U.S. for a third consecutive annual decline after -9.1% (2024) and -15.4% (2025).
Monitor the $14.9B for further cancellations or delays in conversion.
Track Data Solutions unit performance and whether additional follows the $465M charged in 2025.
The company regularly reviews FX exposures and may use , but had no open contracts at December 31, 2025.
Interest rate risk stems from cash, cash equivalents, and , managed by monitoring the portfolio and market trends.
At December 31, 2025, 73% of outstanding debt was fixed-rate; variable-rate debt is unhedged due to its quantum, exposing the company to higher interest costs.
A hypothetical 1% increase in market interest rates would increase net by approximately $4.4 million, while a 1% decrease would reduce it by about $4.4 million.
Material weaknesses in internal controls and a $364.2M goodwill impairment highlight financial reporting and operational risks for FY2025.
⌄
in internal control over financial reporting and disclosure controls led to ineffective assessments as of December 31, 2025, delaying filings and risking stock delisting or breaches.
A $364.2 million charge was recorded for the Data Solutions reporting unit, reflecting potential overvaluation of past acquisitions.
The Company carries $3.4 billion in , with variable-rate exposure on 27% of borrowings, and must comply with restrictive covenants that could limit financial flexibility.
Customer concentration persists, with the top five clients representing 24.8% of , and the loss of large contracts or failure to win new awards could materially impact results.
Regulatory and compliance risks are elevated due to the ongoing SEC investigation, potential FCPA/GDPR violations, and evolving AI and data privacy laws.
Operational risks include reliance on patient and investigator recruitment, potential service errors, and challenges in integrating acquisitions or developing new services.
ICON is a global CRO providing outsourced clinical development, laboratory, and consulting services to pharma, biotech, and medical device firms.
⌄
ICON operates as a pure-play CRO with services spanning Phases I-IV, peri/post-approval, data solutions, site/patient access, and laboratory testing.
is geographically diversified: 30.6% U.S., 57.9% Europe, 11.5% Rest of World in FY2025, with top five customers at 24.8% and no single client over 10%.
The company competes with large global CROs like IQVIA and PAREXEL, differentiating through therapeutic expertise, technology, and patient/site networks like Accellacare.
ICON’s strategy focuses on patient access, enduring partnerships, applied innovation, and being an employer of choice, supported by acquisitions and organic investment.
At year-end 2025, ICON had $14.9 billion in and approximately 40,100 employees across 55 countries.